

Efficacy of group acceptance & commitment therapy in fibromyalgia

Submission date 11/08/2012	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 16/08/2012	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 11/08/2016	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Fibromyalgia is a long-term (chronic) condition that causes pain all over the body. The effects of psychological treatments for fibromyalgia are relatively small but comparable to those reported for drug treatments used for this disorder. Acceptance and commitment therapy, a form of talking therapy, is a promising treatment for chronic pain disorders, but so far there are no studies on fibromyalgia. The aim of this study is to assess the effectiveness of group acceptance and commitment therapy for the treatment of fibromyalgia.

Who can participate?

Patients aged 18–65 with fibromyalgia

What does the study involve?

Participants are randomly allocated to one of three groups. Participants in the first group attend an 8-week group acceptance and commitment therapy program. Participants in the second group receive the recommended pharmacological (drug) treatment for fibromyalgia.

Participants in the third group are put on a waiting list for treatment. Fibromyalgia symptoms are assessed in all three groups after 6 months.

What are the possible benefits and risks of participating?

Possible benefits include an improvement in fibromyalgia symptoms with either of the two treatments as has been demonstrated in previous studies. The risks in the acceptance and commitment therapy group are minimal. In the drug treatment group the drugs used may have minor side effects.

Where is the study run from?

Spanish Research Network of Preventative Activities in Primary Care, Instituto de Salud Carlos III, from the Spanish Ministry of Health

When is the study starting and how long is it expected to run for?

September 2012 to June 2013

Who is funding the study?
Spanish Research Network of Preventative Activities in Primary Care, Instituto de Salud Carlos III,
from the Spanish Ministry of Health

Who is the main contact?
Prof. Javier Garcia-Campayo
jgarcamp@arrakis.es

Contact information

Type(s)
Scientific

Contact name
Prof Javier Garcia-Campayo

Contact details
Miguel Servet University Hospital
Avda Isabel la Catolica 1
Zaragoza
Spain
50009
+34 (0)976 253621
jgarcamp@arrakis.es

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
Protocol 7/2011

Study information

Scientific Title
EFFicacy of Group Acceptance & Commitment Therapy in fibromyalgia (EFFIGACT): a three-
armed randomized controlled trial

Acronym
EFFIGACT

Study objectives
Group acceptance & commitment therapy will be more effective than recommended
pharmacological treatment and more effective than wait-list for the treatment of fibromyalgia
(FM).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Aragón Ethical Review Board, 06/05/2011, ref: 07/2011

Study design

Randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Fibromyalgia (chronic pain conditions)

Interventions

Patients with FM will be randomly assigned to:

Group Acceptance & Commitment Therapy (GACT):

Consists of an 8-week structured program in groups (90 minutes duration, 12-15 participants in each group) based on Acceptance & Commitment Therapy and specifically tailored for fibromyalgia.

Recommended pharmacological treatment:

Pharmacological treatment as recommended by Clinical Guidelines. In summary, main treatment: pregabalin (300-600mg/day), and whether depression is diagnosed duloxetine (60-120 mg/day). Analgesics, hypnotics and other symptomatic treatments are allowed following guides.

Wait-list:

No active treatment will be offered during the period of study.

Intervention Type

Mixed

Primary outcome measure

Fibromyalgia Impact Questionnaire (FIQ) - a 10-item self-report questionnaire developed to measure the health status of FM patients

Secondary outcome measures

1. Sociodemographic variables (gender, age, marital status, ethnic group, living arrangements, educational level, employment status and income)
2. Psychiatric diagnosis (assessed with MINI)
3. Pain catastrophising scale
4. Pain visual analog scale
5. Chronic Pain Acceptance Questionnaire
6. Pain threshold assessed by sphygmomanometer
7. Hospital Anxiety Depression Scale

Overall study start date

01/09/2012

Completion date

30/06/2013

Eligibility

Key inclusion criteria

1. Patients will be recruited from the primary care health centres in the region of Aragon, Spain
2. Patients aged 18-65 years, able to understand and read Spanish
3. Patients who fulfil criteria for FM according to the American College of Rheumatology criteria
4. Patients with no previous psychological treatment during previous year
5. Patients with signed informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

150 participants, 50 patients in each of the three arms.

Key exclusion criteria

1. Patients with severe Axis I psychiatric disorders (dementia, schizophrenia, paranoid disorder, alcohol and/or drug use disorders)
2. Patients with severe somatic disorders which, from the clinicians point of view, prevent patients from carrying out a psychological assessment
3. Patients participating in other clinical trials

Date of first enrolment

01/09/2012

Date of final enrolment

30/06/2013

Locations

Countries of recruitment

Spain

Study participating centre

Miguel Servet University Hospital

Zaragoza

Spain

50009

Sponsor information

Organisation

Miguel Servet University Hospital (Spain)

Sponsor details

c/o Javier Garcia Campayo

Department of Psychiatry

Avda Isabel La Catolica 1

Zaragoza

Spain

50009

+34 (0)976 253621

jgarcamp@arrakis.es

Sponsor type

Hospital/treatment centre

Website

<http://sectorzaragozados.salud.aragon.es/>

ROR

<https://ror.org/01r13mt55>

Funder(s)

Funder type

Research organisation

Funder Name

The Aragon Health Sciences Institute [Instituto Aragonés de Ciencias de la Salud (I+CS)] (Spain)

Funder Name

The Research Network on Preventative Activities and Health Promotion [Red de Actividades Preventivas y de Promoción de la Salud (REDIAPP)] (Spain) ref: B76 & RD06/0018/0020

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2014		Yes	No